Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Cash from Discontinued Operations (2016)

Historic Cash from Discontinued Operations for Ligand Pharmaceuticals (LGNYZ) over the last 4 years, with Q4 2016 value amounting to -$1.1 million.

  • Ligand Pharmaceuticals' Cash from Discontinued Operations changed N/A to -$1.1 million in Q4 2016 from the same period last year, while for Jun 2017 it was -$1.1 million, marking a year-over-year decrease of 20000.0%. This contributed to the annual value of -$642000.0 for FY2013, which is 2866.67% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Cash from Discontinued Operations stood at -$1.1 million for Q4 2016.
  • In the past 5 years, Ligand Pharmaceuticals' Cash from Discontinued Operations ranged from a high of $1.1 million in Q1 2016 and a low of -$1.1 million during Q4 2016
  • Over the past 3 years, Ligand Pharmaceuticals' median Cash from Discontinued Operations value was -$350000.0 (recorded in 2012), while the average stood at -$257000.0.
  • Examining YoY changes over the last 5 years, Ligand Pharmaceuticals' Cash from Discontinued Operations showed a top increase of 22100.0% in 2013 and a maximum decrease of 22100.0% in 2013.
  • Over the past 3 years, Ligand Pharmaceuticals' Cash from Discontinued Operations (Quarter) stood at -$350000.0 in 2012, then crashed by 83.43% to -$642000.0 in 2013, then plummeted by 77.41% to -$1.1 million in 2016.
  • Its last three reported values are -$1.1 million in Q4 2016, $1.1 million for Q1 2016, and -$642000.0 during Q1 2013.